Generated Narrative: Citation 267246 version: 12; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. identifier: FEvIR Object Identifier/267246, https://pubmed.ncbi.nlm.nih.gov/11232013, <a href="http://terminology.hl7.org/7.0.1/NamingSystem-uri.html" title="As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt #xD;#xA;#xD;#xA;This oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: #xD;#xA;#xD;#xA;Note that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.#xD;#xA;#xD;#xA;This OID may also be used in CD.codeSystem.">Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.46 version: 1.0.0-ballot3 title: 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. status: Active date: 2026-01-13 11:03:07+0000 author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: HL7 International / Clinical Decision Support contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base jurisdiction: World copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2001-04-12 lastReviewDate: 2018-11-30 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2001-03-07 10:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2001-04-17 10:01:00+0000 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2001-03-07 10:00:00+0000 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/11232013, https://doi.org/10.1210/jcem.86.1.7157 Titles - Type Text * Primary title Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Abstracts - Type Text * Primary human use This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions. relatesTo type: Correction In classifier: Published Erratum citation: J Clin Endocrinol Metab 2001 Apr;86(4):1659 relatesTo type: Correction In classifier: Published Erratum citation: J Clin Endocrinol Metab. 2002 Feb;2(1):iv. publicationForm publishedIn type: Periodical identifier: Print ISSN Type/0021-972X, ISOAbbreviation/J Clin Endocrinol Metab, ISSN Linking/0021-972X, Medline Title Abbreviation/J Clin Endocrinol Metab, NLM Unique ID/0375362 title: The Journal of clinical endocrinology and metabolism publisherLocation: United States citedMedium: Print volume: 86 issue: 1 articleDate: 2001-01 pageString: 280-8 WebLocations - Classifier Url * Abstract https://pubmed.ncbi.nlm.nih.gov/11232013/ classification type: Publishing Model classifier: Print classification type: Chemical classifier: Blood Glucose, Hypoglycemic Agents, Thiazoles, Thiazolidinediones, Rosiglitazone classification type: MeSH heading artifactAssessment: ArtifactAssessment: artifact[x] = this resource classification type: Publication type classifier: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial classification type: Knowledge Artifact Type classifier: Journal Article artifactAssessment: Classifier added by Computable Publishing LLC classification type: Citation subset classifier: IM contributorship complete: true entry contributor: Lebovitz HE forenameInitials: HE affiliation: Department of Medicine, State University of New York, Brooklyn, New York 11203, USA. hlebovitz@attglobal.net entry contributor: Dole JF forenameInitials: JF entry contributor: Patwardhan R forenameInitials: R entry contributor: Rappaport EB forenameInitials: EB entry contributor: Freed MI forenameInitials: MI entry contributor: Rosiglitazone Clinical Trials Study Group Generated Narrative: Practitioner #contributor0 name: H E Lebovitz Generated Narrative: Practitioner #contributor1 name: J F Dole Generated Narrative: Practitioner #contributor2 name: R Patwardhan Generated Narrative: Practitioner #contributor3 name: E B Rappaport Generated Narrative: Practitioner #contributor4 name: M I Freed Generated Narrative: Organization #contributor5 name: Rosiglitazone Clinical Trials Study Group Generated Narrative: ArtifactAssessment #meshHeading0 artifact: Citation 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. content type: components (if present) include qualifier codings classifier: Aged freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Aged, 80 and over freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Blood Glucose freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: analysis Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Diabetes Mellitus, Type 2 freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: blood Components - Type Classifier * is Major topic No component type: qualifier classifier: drug therapy Components - Type Classifier * is Major topic Yes component type: qualifier classifier: physiopathology Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Double-Blind Method freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Female freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Humans freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Hypoglycemic Agents freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: adverse effects Components - Type Classifier * is Major topic No component type: qualifier classifier: therapeutic use Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Islets of Langerhans freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: drug effects Components - Type Classifier * is Major topic No component type: qualifier classifier: physiopathology Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Male freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Middle Aged freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Rosiglitazone freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Single-Blind Method freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Thiazoles freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: adverse effects Components - Type Classifier * is Major topic No component type: qualifier classifier: therapeutic use Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Thiazolidinediones freeToShare: true Components - Type Classifier * qualifier is Major topic
Rosiglitazone Clinical Trials Study Group
components (if present) include qualifier codings
11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
Computable Publishing®: MEDLINE-to-FEvIR Converter
HL7 International / Clinical Decision Support
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
National Library of Medicine, Index Section
Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events. Rosiglitazone (2 and 4 mg bd) decreased mean hemoglobin A(1c) relative to placebo by 1.2 and 1.5 percentage points, respectively, and reduced fasting plasma glucose concentrations relative to placebo by 3.22 and 4.22 mmol/L, respectively. Fasting plasma insulin and insulin precursor molecules decreased significantly. Homeostasis model assessment estimates indicate that rosiglitazone (2 and 4 mg bd) reduced insulin resistance by 16.0% and 24.6%, respectively, and improved ss-cell function over baseline by 49.5% and 60.0%, respectively. Urinary albumin excretion decreased significantly in the rosiglitazone (4 mg bd) group. There was no increase in adverse events with rosiglitazone. In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions.
J Clin Endocrinol Metab 2001 Apr;86(4):1659
J Clin Endocrinol Metab. 2002 Feb;2(1):iv.
The Journal of clinical endocrinology and metabolism
Classifier added by Computable Publishing LLC
Department of Medicine, State University of New York, Brooklyn, New York 11203, USA. hlebovitz@attglobal.net